Purpose: Prednisolone Acetate (PAC) is currently marketed as micronized ophthalmic suspension. The microsuspension has poor dose accuracy and efficacy due to aggregation, slow dissolution rate and limited corneal residence. The ophthalmic nanosuspension of PAC shall show enhanced solubility, dissolution rate and corneal adhesion due to small particle size and increased surface area.
Methods: In the current work, we prepared ophthalmic formulation of PAC using a novel, spray drying based technology. Firstly, PAC nanocrystalline solid dispersions (NCSD) were prepared using Mannitol (MAN) as the crystallization inducing excipient and two separate stabilizers, Polyvinyl Alcohol (PAC_MAN_PVA) and Vitamin E Tocopheryl Polyethylene Glycol Sulphosuccinate (PAC_MAN_TPGS). The NCSD was dispersed in an aqueous vehicle to obtain an ophthalmic nanosuspension.
Results: The composition, PAC_MAN_PVA (0.3:0.67:0.03%), was pursued due to absence of crystal growth on storage at 40°C/75%RH for 3 months. The resulting nanosuspension showed crystal size, osmolality and viscosity of 590 ± 165 nm, 297 ± 6 mOsm/L and 11 ± 8cP respectively. In 1%w/v SLS media, the nanosuspension showed rapid and complete dissolution of PAC in 120 s. Ex-vivo goat corneal permeation and adhesion study revealed that in comparison to microsuspension, a higher fraction (6.2 times) of nanosuspension adhered to the cornea. Safety studies performed using corneal histopathology and Hen Egg Test- Chorio Allantoic Membrane (HET-CAM) assay showed no physical change in cornea or capillary damage, respectively.
Conclusions: The NCSD can be explored for generation of ophthalmically acceptable nanosuspensions of poorly soluble drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11095-021-02985-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nanocarrier-Based, ocular drug delivery: Challenges, prospects, and the therapeutic landscape in the United Arab Emirates.
Int J Pharm
December 2024
Consultant Ophthalmologist, Ultra Medical Center, Al Ain, United Arab Emirates.
Human eyes have the most complex and advanced physiological defense barriers. Due to these barriers, efficient delivery of ocular drugs is a major challenge in the treatment of eye diseases and disorders. Posterior eye diseases such as retinopathy are the leading causes of impaired vision and blindness globally.
View Article and Find Full Text PDFUtilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations.
Pharmaceutics
October 2024
Laboratory of Food, Drugs and Cosmetics (LTMAC), University of Brasilia, Brasilia 70910-900, Brazil.
Unlabelled: This study aimed to investigate the feasibility of using the digital image processing technique, developed to semi-quantitatively study dermal penetration, to study corneal penetration in an ex vivo porcine eye model. Here, we investigated various formulation strategies intended to enhance dermal and corneal bioavailability of the model hydrophobic drug, curcumin.
Methods: Several formulation principles were explored, including oily solutions, oily suspensions, aqueous nanosuspension, micelles, liposomes and cyclodextrins.
Exploring Hydrogel Nanoparticle Systems for Enhanced Ocular Drug Delivery.
Gels
September 2024
Department of Ophthalmology and Visual Science, University of Illinois, Chicago, IL 60612, USA.
Drug delivery to the ocular system is affected by anatomical factors like the corneal epithelium, blinking reflex, aqueous blood barrier, and retinal blood barrier, which lead to quick removal from the site and inefficient drug delivery. Developing a drug delivery mechanism that targets specific eye tissue is a major hurdle for researchers. Our study examines the challenges of drug absorption in these pathways.
View Article and Find Full Text PDFNovel Small Molecules with Anti-Inflammatory and Anti-Angiogenic Activity in a Mouse Model of Oxygen-Induced Retinopathy.
Cells
August 2024
AyuVis Research Inc., Fort Worth, TX 76107, USA.
Retinopathy of prematurity (ROP) has a dual-phase disease pathology; in phase 1, hyperoxia-induced vaso-obliteration occurs in the retinal vasculature due to increased oxidative stress (OS) and inflammation, followed by phase 2, where hypoxia increases the overproduction of growth factors, inducing retinal neovascularization. Toll-like receptor 2 and -4 (TLR2 and TLR4) overactivation, hyper-inflammation, macrophages, and neutrophil infiltration contribute to the developing ROP. AVR-121 and AVR-123 are novel classes of small-molecule dual inhibitors of TLR2/4 tested in a human leukemia monocytic cell line (THP-1) and cord-blood-derived mononuclear cells (CBMCs).
View Article and Find Full Text PDFDeferasirox nanosuspension loaded dissolving microneedles for ocular drug delivery.
Int J Pharm
October 2024
School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, United Kingdom. Electronic address:
Article Synopsis
- Deferasirox (DFS) is an oral iron chelator used as a neuroprotectant for retinal diseases, but traditional oral administration has drawbacks like frequent dosing and first-pass metabolism.
- Researchers developed a nanosuspension of DFS that significantly improved solubility and stability, and loaded it into polymeric microneedles (MNs) for painless drug delivery to the eye.
- The microneedles showed effective scleral penetration and high drug deposition, indicating that this method is a promising alternative for delivering DFS to treat retinal conditions while maintaining cell viability and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!